Evidence map›Paper›PMID 39479448›Full record

ReviewTheranostics2024

Aspects and prospects of preclinical theranostic radiopharmaceutical development.

Bryce J B Nelson, Viktoria Krol, Aditya Bansal, Jan D Andersson, Frank Wuest, Mukesh K Pandey

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026
    Review
  3. Article
  4. Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bryce J B NelsonDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Viktoria KrolDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Aditya BansalDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Jan D AnderssonDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2 Canada.
Frank WuestDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2 Canada.
Mukesh K PandeyDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article provides an overview of preclinical theranostic radiopharmaceutical development, highlighting aspects of the preclinical development stages that can lead towards a clinical trial. The key stages of theranostic radiopharmaceutical development are outlined, including target selection, tracer development, radiopharmaceutical synthesis, automation and quality control,

Indexed as

RadiopharmaceuticalsAnimalsDrug DevelopmentDrug Evaluation, PreclinicalHumansTheranostic NanomedicineRadiopharmaceuticalsAlpha therapyBeta therapyNuclear MedicinePETSPECTTheranostics

Identifiers

PMID39479448
PMCPMC11519794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.